Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs WeightRx

AbundRX
Graded #181

Lower grade

vs+5.5
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 66.6/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +24
67
91
Dose & formulationEven
64
64
Clinical oversightWeightRx +3
79
82
Labs & monitoringEven
53
53
FulfillmentAbundRX +9
74
65
Contract termsEven
55
55
AbundRX · left barWeightRx · right bar

The numbers

MetricAbundRXWeightRx
WeighScore66.6/10072.1/100
GradeCC
Scorecard rank#181#85
Semaglutide$179/mo (compounded)$250/mo (compounded)
Tirzepatide$279/mo (compounded)$83/mo (term not published, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard